+
データを開く
-
基本情報
登録情報 | データベース: PDB / ID: 5j13 | ||||||
---|---|---|---|---|---|---|---|
タイトル | Structural basis for TSLP antagonism by the therapeutic antibody Tezepelumab (MEDI9929 / AMG-157) | ||||||
![]() |
| ||||||
![]() | IMMUNE SYSTEM / cytokine inflammation TSLP antibody | ||||||
機能・相同性 | ![]() positive regulation of chemokine (C-C motif) ligand 1 production / interleukin-7 receptor binding / positive regulation of granulocyte colony-stimulating factor production / positive regulation of mast cell activation / positive regulation of cytokine-mediated signaling pathway / positive regulation of receptor signaling pathway via STAT / interleukin-7-mediated signaling pathway / positive regulation of interleukin-13 production / positive regulation of interleukin-5 production / positive regulation of interleukin-10 production ...positive regulation of chemokine (C-C motif) ligand 1 production / interleukin-7 receptor binding / positive regulation of granulocyte colony-stimulating factor production / positive regulation of mast cell activation / positive regulation of cytokine-mediated signaling pathway / positive regulation of receptor signaling pathway via STAT / interleukin-7-mediated signaling pathway / positive regulation of interleukin-13 production / positive regulation of interleukin-5 production / positive regulation of interleukin-10 production / cell surface receptor signaling pathway via JAK-STAT / defense response to fungus / positive regulation of chemokine production / Interleukin-7 signaling / cytokine activity / positive regulation of interleukin-6 production / positive regulation of inflammatory response / cytokine-mediated signaling pathway / antimicrobial humoral immune response mediated by antimicrobial peptide / defense response to Gram-negative bacterium / positive regulation of cell population proliferation / negative regulation of apoptotic process / extracellular space / extracellular region 類似検索 - 分子機能 | ||||||
生物種 | ![]() | ||||||
手法 | ![]() ![]() ![]() | ||||||
![]() | Verstraete, K. / Savvides, S.N. | ||||||
![]() | ![]() タイトル: Structure and antagonism of the receptor complex mediated by human TSLP in allergy and asthma. 著者: Kenneth Verstraete / Frank Peelman / Harald Braun / Juan Lopez / Dries Van Rompaey / Ann Dansercoer / Isabel Vandenberghe / Kris Pauwels / Jan Tavernier / Bart N Lambrecht / Hamida Hammad / ...著者: Kenneth Verstraete / Frank Peelman / Harald Braun / Juan Lopez / Dries Van Rompaey / Ann Dansercoer / Isabel Vandenberghe / Kris Pauwels / Jan Tavernier / Bart N Lambrecht / Hamida Hammad / Hans De Winter / Rudi Beyaert / Guy Lippens / Savvas N Savvides / ![]() ![]() ![]() 要旨: The pro-inflammatory cytokine thymic stromal lymphopoietin (TSLP) is pivotal to the pathophysiology of widespread allergic diseases mediated by type 2 helper T cell (Th2) responses, including asthma ...The pro-inflammatory cytokine thymic stromal lymphopoietin (TSLP) is pivotal to the pathophysiology of widespread allergic diseases mediated by type 2 helper T cell (Th2) responses, including asthma and atopic dermatitis. The emergence of human TSLP as a clinical target against asthma calls for maximally harnessing its therapeutic potential via structural and mechanistic considerations. Here we employ an integrative experimental approach focusing on productive and antagonized TSLP complexes and free cytokine. We reveal how cognate receptor TSLPR allosterically activates TSLP to potentiate the recruitment of the shared interleukin 7 receptor α-chain (IL-7Rα) by leveraging the flexibility, conformational heterogeneity and electrostatics of the cytokine. We further show that the monoclonal antibody Tezepelumab partly exploits these principles to neutralize TSLP activity. Finally, we introduce a fusion protein comprising a tandem of the TSLPR and IL-7Rα extracellular domains, which harnesses the mechanistic intricacies of the TSLP-driven receptor complex to manifest high antagonistic potency. | ||||||
履歴 |
|
-
構造の表示
構造ビューア | 分子: ![]() ![]() |
---|
-
ダウンロードとリンク
-
ダウンロード
PDBx/mmCIF形式 | ![]() | 202.4 KB | 表示 | ![]() |
---|---|---|---|---|
PDB形式 | ![]() | 160 KB | 表示 | ![]() |
PDBx/mmJSON形式 | ![]() | ツリー表示 | ![]() | |
その他 | ![]() |
-検証レポート
文書・要旨 | ![]() | 447.5 KB | 表示 | ![]() |
---|---|---|---|---|
文書・詳細版 | ![]() | 447.5 KB | 表示 | |
XML形式データ | ![]() | 20.1 KB | 表示 | |
CIF形式データ | ![]() | 28 KB | 表示 | |
アーカイブディレクトリ | ![]() ![]() | HTTPS FTP |
-関連構造データ
-
リンク
-
集合体
登録構造単位 | ![]()
| ||||||||
---|---|---|---|---|---|---|---|---|---|
1 |
| ||||||||
単位格子 |
| ||||||||
Components on special symmetry positions |
|
-
要素
#1: タンパク質 | 分子量: 16523.906 Da / 分子数: 1 変異: Residues 127 to 131 were deleted in the construct used for crystallisation. 由来タイプ: 組換発現 詳細: Before crystallisation, the N-terminal His-tag (residues 1 - 17, MGSSHHHHHHSSGLVPR) was removed by thrombin cleavage. Residues 127 to 131 of TSLP (127-RRKRK-131) (according to the reference ...詳細: Before crystallisation, the N-terminal His-tag (residues 1 - 17, MGSSHHHHHHSSGLVPR) was removed by thrombin cleavage. Residues 127 to 131 of TSLP (127-RRKRK-131) (according to the reference sequence numbering scheme for TSLP) were deleted in the construct used for crystallization. 由来: (組換発現) ![]() 詳細 (発現宿主): ORF cloned between NdeI and BamHI sites 発現宿主: ![]() ![]() | ||||
---|---|---|---|---|---|
#2: 抗体 | 分子量: 25870.895 Da / 分子数: 1 / 由来タイプ: 組換発現 詳細: The signal peptide (residues 1 - 28) is removed from the mature protein. 由来: (組換発現) ![]() 詳細 (発現宿主): ORF cloned between AgeI and KpnI sites 細胞株 (発現宿主): HEK-293T / 発現宿主: ![]() | ||||
#3: 抗体 | 分子量: 28438.221 Da / 分子数: 1 / 由来タイプ: 組換発現 詳細: The signal peptide (residues 1 - 28) is removed from the mature protein. 由来: (組換発現) ![]() 詳細 (発現宿主): ORF cloned between AgeI and KpnI sites 細胞株 (発現宿主): HEK-293T / 発現宿主: ![]() | ||||
#4: 化合物 | #5: 水 | ChemComp-HOH / | Has protein modification | Y | |
-実験情報
-実験
実験 | 手法: ![]() |
---|
-
試料調製
結晶 | マシュー密度: 2.26 Å3/Da / 溶媒含有率: 45.49 % |
---|---|
結晶化 | 温度: 293 K / 手法: 蒸気拡散法, シッティングドロップ法 / pH: 4.6 詳細: 0.2 M ammonium sulfate 0.1 M sodium acetate pH 4.6 25% w/v polyethylene glycol 4000 |
-データ収集
回折 | 平均測定温度: 100 K |
---|---|
放射光源 | 由来: ![]() ![]() ![]() |
検出器 | タイプ: DECTRIS EIGER X 9M / 検出器: PIXEL / 日付: 2015年12月17日 |
放射 | モノクロメーター: Si[111] / プロトコル: SINGLE WAVELENGTH / 単色(M)・ラウエ(L): M / 散乱光タイプ: x-ray |
放射波長 | 波長: 0.9801 Å / 相対比: 1 |
反射 | 解像度: 2.298→55 Å / Num. obs: 25284 / % possible obs: 97 % / 冗長度: 8.4 % / Biso Wilson estimate: 47.33 Å2 / CC1/2: 0.998 / Rrim(I) all: 0.11 / Net I/σ(I): 14.23 |
反射 シェル | 解像度: 2.298→2.44 Å / 冗長度: 4.2 % / Mean I/σ(I) obs: 1.6 / Rrim(I) all: 0.747 / % possible all: 83.8 |
-
解析
ソフトウェア |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
精密化 | 構造決定の手法: ![]() 開始モデル: 4HK0, chain B; 4HIE, chain B 解像度: 2.298→44.796 Å / SU ML: 0.3 / 交差検証法: FREE R-VALUE / σ(F): 1.39 / 位相誤差: 23.26 詳細: - rigid body refinement (single rigid body per domain) - Iterative cycles of refinement, model (re)building and validation xyz coordinate refinement real-space refinement individual B-factors ...詳細: - rigid body refinement (single rigid body per domain) - Iterative cycles of refinement, model (re)building and validation xyz coordinate refinement real-space refinement individual B-factors riding hydrogens optimisation of X-ray/stereochemistry weight optimisation of X-ray/ADP weight structure validation in COOT, Phenix (Molprobity) and PDB_REDO
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
溶媒の処理 | 減衰半径: 0.9 Å / VDWプローブ半径: 1.11 Å | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
精密化ステップ | サイクル: LAST / 解像度: 2.298→44.796 Å
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
拘束条件 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
LS精密化 シェル |
|